PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
10814503-4	2000	VEGF secretion was also increased by other PPARgamma agonists, pioglitazone, LY171883, and 15d-PGJ2 (224 +/- 17.1%, 247 +/- 36.8% and 171 +/- 7.8%, respectively), but not the PPARgamma agonists bezafibrate and Wy14643 (85.2 +/- 1.5%, 94.6 +/- 3.2, respectively).	Pioglitazone	63-75	vascular endothelial growth factor A	Homo sapiens	0-4	
27347105-1	2016	The aim of the retrospective study was to analyze the effect of pioglitazone on the expression of tumor tissue inflammation factor interleukin (IL)-8, macrophage colony-stimulating factor (M-CSF) and vascular endothelial growth factor (VEGF) of type II diabetes in bladder cancer patients.	Pioglitazone	64-76	vascular endothelial growth factor A	Homo sapiens	200-234	
30678291-4	2019	Pioglitazone increased the proliferation of MSCs and enhanced the secretion of VEGF (vascular endothelial growth factor) and collagen in these cells.	Pioglitazone	0-12	vascular endothelial growth factor A	Homo sapiens	79-83	
30678291-4	2019	Pioglitazone increased the proliferation of MSCs and enhanced the secretion of VEGF (vascular endothelial growth factor) and collagen in these cells.	Pioglitazone	0-12	vascular endothelial growth factor A	Homo sapiens	85-119	
18758684-5	2009	The level of VEGF, IL-8 and Angiogenin were increased in pioglitazone than rosiglitazone group.	Pioglitazone	57-69	vascular endothelial growth factor A	Homo sapiens	13-17	
24913817-8	2014	In addition, pioglitazone and miR125a overexpression elicit similar phenotypic responses, including suppression of both proliferation and VEGF production.	Pioglitazone	13-25	vascular endothelial growth factor A	Homo sapiens	138-142	
19520186-7	2009	There was 40% decrease in proliferation with pioglitazone in VEGF stimulated cells, which was reversed by insulin.	Pioglitazone	45-57	vascular endothelial growth factor A	Homo sapiens	61-65	
19520186-8	2009	ERK 1/2 activation was decreased by pioglitazone in VEGF stimulated cells and was partially reversed by insulin.	Pioglitazone	36-48	vascular endothelial growth factor A	Homo sapiens	52-56	
17786343-8	2007	Increase of apoptosis and necrosis as well as decrease of VEGF expression and MVD were found in solid OVCAR-3 tumors treated with CA, pioglitazone or the combination.	Pioglitazone	134-146	vascular endothelial growth factor A	Homo sapiens	58-62	
18810647-0	2008	PPAR gamma ligands, rosiglitazone and pioglitazone, inhibit bFGF- and VEGF-mediated angiogenesis.	Pioglitazone	38-50	vascular endothelial growth factor A	Homo sapiens	70-74	
18810647-1	2008	OBJECTIVE: To study the effect of peroxisome proliferator-activated receptor-gamma (PPAR gamma) agonists, pioglitazone and rosiglitazone, on vascular endothelial growth factor (VEGF)- and basic fibroblast growth factor (bFGF)-induced angiogenesis and on endothelial cell migration.	Pioglitazone	106-118	vascular endothelial growth factor A	Homo sapiens	141-175	
18810647-1	2008	OBJECTIVE: To study the effect of peroxisome proliferator-activated receptor-gamma (PPAR gamma) agonists, pioglitazone and rosiglitazone, on vascular endothelial growth factor (VEGF)- and basic fibroblast growth factor (bFGF)-induced angiogenesis and on endothelial cell migration.	Pioglitazone	106-118	vascular endothelial growth factor A	Homo sapiens	177-181	
18810647-4	2008	RESULTS: Pioglitazone and rosiglitazone inhibited the pro-angiogenic effects of bFGF and VEGF in the CAM model significantly (P < 0.001) to the same extent.	Pioglitazone	9-21	vascular endothelial growth factor A	Homo sapiens	89-93	
16508777-9	2006	Mean VEGF increased with pioglitazone (61.1 pg/ml), but not significantly more than placebo (9.76 pg/ml, p=0.94).	Pioglitazone	25-37	vascular endothelial growth factor A	Homo sapiens	5-9	
16505497-5	2006	RESULTS: Pioglitazone increased (P < 0.001 from baseline) total body water (+2.4 +/- 0.5 l) accounting for 75% of the total weight gain (+3.1 +/- 2.0 kg) but did not alter vascular endothelial growth factor concentrations.	Pioglitazone	9-21	vascular endothelial growth factor A	Homo sapiens	175-209